

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
Michael Wittekind	03/08/2010
Raymond J. Paxton	03/05/2010
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	Amgen Inc.
<b>Street Address:</b>	One Amgen Center Drive
<b>Internal Address:</b>	Law Department
<b>City:</b>	Thousand Oaks
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	91320-1799
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	12595585
<b>CORRESPONDENCE DATA</b>	
Fax Number:	(206)233-0644
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	206-265-7000
Email:	kertsonn@amgen.com
Correspondent Name:	Nanci M. Kertson
Address Line 1:	1201 Amgen Court West
Address Line 2:	Law Department
Address Line 4:	Seattle, WASHINGTON 98119-3105
ATTORNEY DOCKET NUMBER:	A-1418-US-PCT
NAME OF SUBMITTER:	James E. Klaniecki

CH \$40.00 12595585

Total Attachments: 3  
 source=A-1418-US-PCT\_Assignment#page1.tif

**501113309**

**PATENT**  
**REEL: 024049 FRAME: 0730**

source=A-1418-US-PCT\_Assignment#page2.tif

source=A-1418-US-PCT\_Assignment#page3.tif

ASSIGNMENT

Whereas, Michael Wittekind, 13364 Bridgestone Ct. NE, Bainbridge Island, Washington 98110, USA  
Raymond J. Paxton, 6583 156<sup>th</sup> Avenue SE, Bellevue, Washington 98006, USA

have made an invention which is the subject of an application for Letters Patent of the United States ("Application") entitled

IDENTIFICATION AND METHOD FOR USING THE PRE-LIGAND ASSEMBLY DOMAIN OF THE IL-17 RECEPTOR

which is found in:

- (a) the US Patent Application executed on even date herewith; [which claims the benefit of U.S. Provisional Application No. \_\_\_\_\_ filed \_\_\_\_\_.]
- (b) the US Patent Application executed on \_\_\_\_\_ [which claims the benefit of U.S. Provisional Application No. \_\_\_\_\_ filed \_\_\_\_\_.]
- (c) US Application Serial No.: 12/595,585 filed on October 12, 2009  
which claims priority under 35 U.S.C. § 371 of International Application No. PCT/US08/60953,  
having an International filing date of April 20, 2008.
- (d) US Patent No.: \_\_\_\_\_

Whereas AMGEN INC., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California, 91320-1799, wishes to acquire the entire interest in all inventions disclosed in such Application:

Now, therefore, in consideration of the sum of one dollar (\$1.00) and other good and valuable consideration, the receipt of which is hereby acknowledged, we hereby sell, assign, transfer and set over unto AMGEN INC., its successors and assigns (collectively "AMGEN") our entire right, title and interest in, to and under the Application, and any provisional application(s) from which Application is derived, and all priority rights to which the Application may be entitled, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all Letters Patent of the United States and of all other countries which may be granted for such inventions, or any of them, including divisional, continuation, and/or continuation-in-part applications based on the above-identified Application, all such inventions and all rights in such Application and Letters Patent to be held and enjoyed by AMGEN for its own use and enjoyment to the full end of the term or terms for which such Letters Patent may be granted as fully and entirely as the same would have been held and enjoyed by us had this assignment and sale not been made.

Further, we hereby sell, assign, transfer, and set over unto AMGEN our entire right, title and interest in or to the right to refer to, to access, and to control microorganism(s) or other biological material(s) related to the Application and which are deposited by us or at our direction or deposited on our behalf by AMGEN, its affiliates, employees or employees of its affiliates. The transfer of such right, title and interest includes, without limitation, our unreserved and irrevocable consent and authorization to AMGEN to refer to the deposited microorganisms(s) or other biological materials(s) in the Application and the right to make available to the public the deposited material in accordance with the laws, treaties, statutes, rules, regulations and the like of the United States, all other countries, and any patent granting authority or organization.

We authorize and request the Commissioner of Patents and Trademarks of the United States to issue any such Letters Patent which may be granted on the Application to AMGEN as assignee of the entire right, title and interest therein and thereto.

For ourselves and for our legal representatives, we covenant and agree with AMGEN that we have not granted to any others any license to make, use or sell any of such inventions, that our right title and interest in such inventions has not been encumbered, that we have good right and title to sell and assign the same, and that we will not execute any instrument in conflict herewith.

For ourselves and for our heirs, successors and legal representatives, we further covenant and agree with AMGEN that upon request we and they will: (i) execute continuing, divisional or reissue applications, amended specifications, or rightful declarations or oaths; (ii) communicate to AMGEN any facts known to us or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any interference proceedings or litigations; (iv) execute and deliver any application papers, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for AMGEN, may be necessary or desirable to secure the grant of Letters Patent to AMGEN or its nominees, in the United States and in all other countries where AMGEN may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for AMGEN and to vest and confirm in AMGEN or its nominees, the full and complete legal and equitable title to all such Letters Patent, without further consideration than that now paid but at the expense of AMGEN.

In Witness Whereof I have executed this assignment on the 8 day of MARCH 2010

Michael Wittekind  
(Name of Inventor)

Michael Wittekind  
(Signature of Inventor)

**UNITED STATES OF AMERICA**

State of Washington }  
County of King } ss:


March 8, 2010

Before me, a Notary Public for King County, State of Washington, personally appeared  
Michael Wittekind

who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his/her authorized capacity, and that by his/her signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of Washington that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.



Nanci M. Kertson  
Notary Public  
My commission expires  
March 1, 2011

In Witness Whereof I have executed this assignment on the 5<sup>th</sup> day of March 20 10

Raymond J. Paxton  
(Name of Inventor)

Raymond J. Paxton  
(Signature of Inventor)

**UNITED STATES OF AMERICA**

State of King }  
County of Washington } ss:

March 5, 2010 <sup>10</sup> ~~2011~~ *and*

Before me, a Notary Public for King County, State of Washington, personally appeared

Raymond J. Paxton

who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his/her authorized capacity, and that by his/her signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of Washington that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Nanci M. Kertson  
Notary Public

My commission expires  
March 1, 2011

